Analysis of data from 2 large trials finds that cutoffs used to separate different “disease activity states†on the Disease Activity index for Psoriatic Arthritis (DAPSA) are valid. Different disease activity states are associated with different degrees of functional impairment and joint damage progression.
In this Q&A, Rheumatology Network speaks with Dr. Barbara Vilen who is making strides in both basic and translational research that may lead to new therapeutic targets for lupus.
In this Q&A, Rheumatology Network speaks with Dr. Stephen Katz about the NIAMS Action Plan for Lupus Research.
Observed improvements were not statistically significant above placebo, and there remains no approved medication for adolescent sufferers of fibromyalgia.
With the hope of wasting less time on medications doomed to fail, researchers are seeking biomarkers to predict a patient’s response to particular RA treatments.
In this article, we ask the experts to share their thoughts on the roots of doctor-patient communication challenges. Overwhelmed patients, busy doctors and technological communication rose to the top.
Popularly sold to improve joint health, a recent Spanish study found the benefits of CS+GS supplements on par with (and in some cases outperformed by) placebos.
Pain and sleep problems commonly go hand-in-hand. However, obstructive sleep apnea (OSA), daytime sleepiness, and poor sleep quality are all very different things.
Gout’s relationship with food intake can be tricky, so which is better: Eating foods lower on the glycemic index scale or lower in carbohydrates?
The gut microbiome has previously been considered a therapeutic target for the immune system, and new research suggests the microbiome’s composition can hold the key to managing psoriasis.
Saying the Guidelines fill a “significant clinical void,†the organization celebrated awareness of the rheumatic condition with a series of stringently approved recommendations for its treatment.
Biologics only slightly reduce fatigue in rheumatoid arthritis (RA) patients, a systematic review suggests.
In patients with CNS lupus, early evidence shows the presence of the development of dementia, says Dr. Yehuda Shoenfeld of Israel. "Lupus is a disease of young females, so it's not elderly females with dementia at this age."
In this story, we revisit the clinical trials that led to the approval of adalimumab for uveitis.
CPPD disease, once known as pseudogout, is underdiagnosed. A thorough analysis of synovial fluid can help improve outcomes, researchers say.
An unorthodox treatment for rheumatoid arthritis is gaining steam in the laboratory.
What happens when someone with psoriatic arthritis also has fibromyalgia? Researchers from Tel Aviv University in Israel were determined to find out.
Novartis conducted a global survey of 8,338 patients with moderate-to-severe psoriasis across 31 countries to assess patients’ perceptions of what constitutes “clear skin.â€
In patients diagnosed with psoriasis, disease severity has been strongly associated with developing a higher risk of comorbidities affecting the kidney, liver, and pancreas.
The Fibromyalgia Rapid Screening Tool (FiRST) can help physicians make the determination, but just how reliable is it?
Patients suffering from psoriasis are at increased risk of developing serious infections.
Most patients are well-meaning and generally nice. But every now and then, you will get one who is a total pain to deal with. Maybe your patient lies to you, gets sarcastic, asks for special “favors,†or generally just pushes your buttons. We’ve all been there.
It is frustrating, to say the least, when your patients take their frustrations out on you. And, as if having to deal with an angry patient isn’t bad enough, providers now have to worry about the threat of legal action more than ever before.
After the FDA’s March approval of ixekizumab (Taltz/ Eli Lilly and Company), researchers recently confirmed the psoriasis treatment was beneficial even after 60 weeks.
Whether delivered intentionally or not, some physician comments are unhelpful at best and low-blows at worst. Saying certain things to patients can actually increase your risk of having a malpractice suit filed against you, making it especially important for you to always be mindful when speaking with patients.
EULAR 2016: Patient education and compliance often take a back seat to disease management, but they need to be at the forefront of care.
In this Q&A, Dr. Eric Ruderman of Northwestern University Feinberg School of Medicine, addresses the issue of subpar vaccination rates.
When patients can't tolerate methotrexate, it puts doctors in a conundrum, says Dr. Jeffrey Curtis of the University of Alabama in this Q&A.
EULAR 2016: Secukinumab prevents radiographic progression in 80 percent of ankylosing spondylitis patients and provides sustained improvements.